EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
Primary Objective
The primary objective of the study is to assess the safety of nonconforming ide-cel.
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Peter Forsberg, MD
Study ID
Protocol Number: 21-5082
More information available at ClinicalTrials.gov: NCT04771078
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers